I expected at least to see the 30% of autoimmune as positive results. This is very bizarre disappointing and unexpected, I feel as if my Puppy died.
It's just awful news, just so drenching, so demoralizing.
But now more and more I'm starting to wonder maybe folks don't all have the same illness at all.
is it even autoimmune...is it one disease.. racing thoughts...
Phase 2&3 results don't have to contradict each other.Odd how this Fluge and Mella phase III trial failed to find any positive effect, yet Kolibri Medical clinic in Norway reported that rituximab treatment cures ⅓ of ME/CFS patients, makes an improvement in another ⅓ of patients, and has no effect in the final ⅓ of patients. Ref: 1
This Kolibri's results are consistent with the phase II study, which found 60% of patients made a major improvement.
ME/CFS placebo responses were low in the past, but there wasn't much to be optimistic about. Patients had high expectations for this treatment.
I believe it is autoimmune for a sub-group and that it is not one disease. But I of course could be 100% wrong and have nothing solid to back up my opinion.
Did they measure anything that was purely objective and could not be placebo? In my case we measure different blood markers, how long I can stand and walk without wheelchair, spirometry/breathing tests, HR & BP and autonomic measurements, muscle strength, etc.
There were objective measures, but it's unclear if they were negative as well, or if they were referring to only the questionaires. https://clinicaltrials.gov/ct2/show/NCT02229942Did they measure anything that was purely objective and could not be placebo? In my case we measure different blood markers, how long I can stand and walk without wheelchair, spirometry/breathing tests, HR & BP and autonomic measurements, muscle strength, etc. I don't have fatigue (which is hard to "measure" IMO anyway) so I was wondering how they determined if someone was a responder? Was it purely by questionnaires or something objective and measurable?
I don't know about purely objective but they did use Sensewear Armbands but only for a limited period of time.Did they measure anything that was purely objective and could not be placebo?
Also the conducted further studies in parallel to the trial.Physical activity (Sensewear armband) [ Time Frame: Analyzed at baseline and at interval 17-21 months ]
The patients' physical activity level, in a home setting for 7 consecutive days, is recorded using Sensewear armbands, with registration at baseline and repeated in the time interval 17-21 months follow-up. Changes from baseline to analysis during the time interval 17-21 months, for mean number of steps per 24h, maximum number of steps per 24h, mean duration per 24h with activity level at least 3.5 METs, max duration per 24h with activity level at least 3.5 METs, are recorded. The difference between rituximab and placebo groups will constitute secondary endpoints.
Three substudies will be performed:
Endothelial function: assessment of Flow-Mediated Dilation and skin microcirculation at baseline and repeated during the time interval 17-21 months.
Cardiopulmonary exercise test for two following days: assessment at baseline and repeated during the time interval 17-21 months.
Gastrointestinal function: assessment at baseline and repeated during the time interval 17-21 months.
AlmostYes. Failures teach science almost as much as successes.
That was a German soccer player. There was an interview with them, and Miktovits. When they talked she said that with the dosage they gave him that it was no wonder that he became more ill. It's in here somewhere. The intro starts out in German, but the rest is in English.There is a German doc in Munich who is treating a CFS-patient that got much worse under Rituximab. He is completely disabled due to only one injection. I don't know if he has ever recovered... But I think he did not!